<DOC>
	<DOCNO>NCT02510014</DOCNO>
	<brief_summary>A multi-center , open-label , long-term safety study approximately 600 subject diagnose opioid use disorder enrol . Following screening period , subject receive run SUBOXONE sublingual film follow monthly injection open-label high dose RBP-6000 . RBP-6000 dose adjust low dose , back high dose , base medical judgment Investigator . Subjects participate study either 6 12 month .</brief_summary>
	<brief_title>Safety Tolerability Study Depot Buprenorphine Treatment Seeking Subjects With Opioid Use Disorder</brief_title>
	<detailed_description>Approximately 600 subject diagnose opioid use disorder enrol ; approximately 300 subject complete randomized , double-blind , placebo-controlled study , RB-US-13-0001 , approximately 300 subject participate study RB-US-13-0001 . Following informed consent completion screening procedure , subject receive SUBOXONE sublingual film , titrate response . After 4-14 day SUBOXONE film treatment , subject evaluate enrollment study.Eligible subject receive high dose RBP-6000 initial dose , follow monthly injection low high dose RBP-6000 , base medical judgment investigator . Subjects participate study RB-US-13-0001 receive monthly injection 6 month . Subjects participate study RB-US-13-0001 receive monthly injection to12 month . At injection visit continuous electrocardiogram recording pulse oximetry collect prior injection least 4 hour injection . Subjects return clinic every 1-4 week laboratory test , complete study questionnaire , adverse event injection site assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>De novo subject : Seeking treatment opioid use disorder ( OUD ) previous 3 month meet Diagnostic Statistical Manual 5 ( DSM5 ) criteria moderate severe OUD Appropriate candidate opioid partialagonist treatment BMI 18 35 , inclusive Rollover subject : Completed RBUS130001 De novo subject : Current diagnosis , OUD , require chronic opioid treatment Current substance use disorder regard substance opioids , cocaine , cannabis , tobacco alcohol Received medicationassisted treatment OUD 90 day prior informed consent Use ( within past 30 day prior informed consent ) positive urine drug screen ( UDS ) screen barbiturate , benzodiazepine , methadone buprenorphine Treatment OUD require court order History recent suicidal ideation attempt Roll subject : Experienced major protocol deviation adverse event RBUS130001 could potentially compromise subject safety Discontinued early study RBUS130001</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>